Literature DB >> 21912465

Innate and adaptive immunity in inflammatory bowel disease.

Britta Siegmund1, Martin Zeitz.   

Abstract

Inflammatory bowel diseases are the consequence of a dysregulated mucosal immune system. The mucosal immune system consists of two arms, innate and adaptive immunity, that have been studied separately for a long time. Functional studies from in vivo models of intestinal inflammation as well as results from genome-wide association studies strongly suggest a cross-regulation of both arms. The present review will illustrate this interaction by selecting examples from innate immunity and adaptive immunity, and their direct impact on each other. Broadening our view by focusing on the cross-regulated areas of the mucosal immune system will not only facilitate our understanding of disease, but furthermore will allow identification of future therapeutic targets.

Entities:  

Keywords:  Immune system; Inflammatory bowel diseases

Mesh:

Substances:

Year:  2011        PMID: 21912465      PMCID: PMC3158392          DOI: 10.3748/wjg.v17.i27.3178

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  44 in total

1.  Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract.

Authors:  Koichi S Kobayashi; Mathias Chamaillard; Yasunori Ogura; Octavian Henegariu; Naohiro Inohara; Gabriel Nuñez; Richard A Flavell
Journal:  Science       Date:  2005-02-04       Impact factor: 47.728

2.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

3.  Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.

Authors:  Holm H Uhlig; Brent S McKenzie; Sophie Hue; Claire Thompson; Barbara Joyce-Shaikh; Renata Stepankova; Nicolas Robinson; Sofia Buonocore; Helena Tlaskalova-Hogenova; Daniel J Cua; Fiona Powrie
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

4.  Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis.

Authors:  Christoph Becker; Heike Dornhoff; Clemens Neufert; Massimo C Fantini; Stefan Wirtz; Sabine Huebner; Alexei Nikolaev; Hans-Anton Lehr; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Peter R Galle; Margaret Karow; Markus F Neurath
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

5.  Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing.

Authors:  Shin Maeda; Li-Chung Hsu; Hongjun Liu; Laurie A Bankston; Mitsutoshi Iimura; Martin F Kagnoff; Lars Eckmann; Michael Karin
Journal:  Science       Date:  2005-02-04       Impact factor: 47.728

6.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Authors:  Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

7.  NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.

Authors:  J Wehkamp; J Harder; M Weichenthal; M Schwab; E Schäffeler; M Schlee; K R Herrlinger; A Stallmach; F Noack; P Fritz; J M Schröder; C L Bevins; K Fellermann; E F Stange
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

8.  NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Warren Strober
Journal:  Nat Immunol       Date:  2004-06-27       Impact factor: 25.606

9.  Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease.

Authors:  Naohiro Inohara; Yasunori Ogura; Ana Fontalba; Olga Gutierrez; Fernando Pons; Javier Crespo; Koichi Fukase; Seiichi Inamura; Shoichi Kusumoto; Masahito Hashimoto; Simon J Foster; Anthony P Moran; Jose L Fernandez-Luna; Gabriel Nuñez
Journal:  J Biol Chem       Date:  2003-01-04       Impact factor: 5.157

10.  Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection.

Authors:  Stephen E Girardin; Ivo G Boneca; Jérôme Viala; Mathias Chamaillard; Agnès Labigne; Gilles Thomas; Dana J Philpott; Philippe J Sansonetti
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

View more
  17 in total

Review 1.  Animal models of inflammatory bowel disease: a review.

Authors:  Nidhi Goyal; Ajay Rana; Abhilasha Ahlawat; Krishna Reddy V Bijjem; Puneet Kumar
Journal:  Inflammopharmacology       Date:  2014-06-07       Impact factor: 4.473

2.  What's new about inflammatory bowel diseases in 2011.

Authors:  Jonas Mudter
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

3.  Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease.

Authors:  Kriszta Molnár; Adám Vannay; Beáta Szebeni; Nóra Fanni Bánki; Erna Sziksz; Aron Cseh; Hajnalka Győrffy; Péter László Lakatos; Mária Papp; András Arató; Gábor Veres
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

4.  Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.

Authors:  Nicholas Horton; Xianrui Wu; Jessica Philpott; Ari Garber; Jean-Paul Achkar; Aaron Brzezinski; Bret A Lashner; Bo Shen
Journal:  Dig Dis Sci       Date:  2016-09-12       Impact factor: 3.199

5.  Inflammatory Potential of Diet and Risk of Ulcerative Colitis in a Case-Control Study from Iran.

Authors:  Nitin Shivappa; James R Hébert; Samaneh Rashvand; Bahram Rashidkhani; Azita Hekmatdoost
Journal:  Nutr Cancer       Date:  2016-03-30       Impact factor: 2.900

Review 6.  Application of liposomes in drug development--focus on gastroenterological targets.

Authors:  Jian-Xin Zhang; Kun Wang; Zheng-Fa Mao; Xin Fan; De-Li Jiang; Min Chen; Lei Cui; Kang Sun; Sheng-Chun Dang
Journal:  Int J Nanomedicine       Date:  2013-04-08

7.  Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy.

Authors:  Mi Jin Kim; Woo Yong Lee; Yon Ho Choe
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

8.  Cross-regulation of innate and adaptive immunity: a new perspective for the pathogenesis of inflammatory bowel disease.

Authors:  Da Yeon Oh; Seong-Joon Koh
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

9.  Activation of protein tyrosine phosphatase non-receptor type 2 by spermidine exerts anti-inflammatory effects in human THP-1 monocytes and in a mouse model of acute colitis.

Authors:  Belén Morón; Marianne Spalinger; Stephanie Kasper; Kirstin Atrott; Isabelle Frey-Wagner; Michael Fried; Declan F McCole; Gerhard Rogler; Michael Scharl
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

10.  Dysregulation of anti-inflammatory annexin A1 expression in progressive Crohns Disease.

Authors:  Angela Sena; Irina Grishina; Anne Thai; Larissa Goulart; Monica Macal; Anne Fenton; Jay Li; Thomas Prindiville; Sonia Maria Oliani; Satya Dandekar; Luiz Goulart; Sumathi Sankaran-Walters
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.